Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response (Q64104066)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

title

Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Nadia Falzone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Boon Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Katherine A Vallis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

author name string

Javian Malcolm

1

0 references

Nadia Falzone

2

0 references

Boon Q Lee

3

0 references

Katherine A Vallis

4

0 references

language of work or name

English

0 references

publication date

25 February 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

26 April 2020

page(s)

268

0 references

copyright license

start time

25 February 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Naturally occurring antibodies devoid of light chains

1 reference

12 December 2020

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

12 December 2020

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

12 December 2020

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study

1 reference

12 December 2020

Planning combined treatments of external beam radiation therapy and molecular radiotherapy

1 reference

12 December 2020

²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

1 reference

12 December 2020

Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis

1 reference

12 December 2020

Improving external beam radiotherapy by combination with internal irradiation

1 reference

12 December 2020

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

1 reference

12 December 2020

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.

1 reference

12 December 2020

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

1 reference

12 December 2020

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

1 reference

12 December 2020

The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE

1 reference

12 December 2020

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib

1 reference

12 December 2020

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.

1 reference

12 December 2020

68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology

1 reference

12 December 2020

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

1 reference

12 December 2020

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

1 reference

12 December 2020

Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE.

1 reference

12 December 2020

Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine

1 reference

12 December 2020

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

12 December 2020

Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?

1 reference

12 December 2020

Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.

1 reference

12 December 2020

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

1 reference

12 December 2020

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

1 reference

12 December 2020

Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.

1 reference

12 December 2020

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.

1 reference

12 December 2020

Improved outcome of 131I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma

1 reference

12 December 2020

The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer

1 reference

12 December 2020

177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.

1 reference

12 December 2020

Targeted radionuclide therapy in combined-modality regimens.

1 reference

12 December 2020

[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

1 reference

12 December 2020

Somatostatin Receptor Antagonists for Imaging and Therapy

1 reference

12 December 2020

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

1 reference

12 December 2020

Chemokine receptor - Directed imaging and therapy

1 reference

12 December 2020

Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 ((68)Ga-NODAGA-JR11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study

1 reference

12 December 2020

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.

1 reference

12 December 2020

Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Evaluation of Sensitivity in a Prospective Phase II Imaging Study

1 reference

12 December 2020

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.

1 reference

12 December 2020

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

1 reference

12 December 2020

Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control.

1 reference

12 December 2020

Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy.

1 reference

12 December 2020

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept.

1 reference

12 December 2020

Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile

1 reference

12 December 2020

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

1 reference

12 December 2020

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.

1 reference

12 December 2020

Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer.

1 reference

12 December 2020

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

1 reference

12 December 2020

A new method for tumor imaging by targeting cancer associated fibroblasts.

1 reference

12 December 2020

Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

1 reference

12 December 2020

Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases

1 reference

12 December 2020

Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.

1 reference

12 December 2020

Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.

1 reference

12 December 2020

Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model.

1 reference

12 December 2020

Protection of Kidney Function with Human Antioxidation Protein α-Microglobulin in a Mouse Lu-DOTATATE Radiation Therapy Model

1 reference

12 December 2020

The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy

1 reference

12 December 2020

The Relevance of Dosimetry in Precision Medicine

1 reference

12 December 2020

Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy

1 reference

12 December 2020

Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM)

1 reference

12 December 2020

Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy

1 reference

12 December 2020

Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers

1 reference

12 December 2020

Monosodium Glutamate Reduces Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model

1 reference

12 December 2020

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

1 reference

12 December 2020

The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study

1 reference

12 December 2020

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

1 reference

12 December 2020

Enhancing Treatment Efficacy of Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies

1 reference

12 December 2020

Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

1 reference

12 December 2020

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

1 reference

12 December 2020

64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

1 reference

12 December 2020

Identifiers

DOI

10.3390/CANCERS11020268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30823564%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

PubMed publication ID

30823564

1 reference